Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Combo
    Junior Member
    • Sep 2009
    • 8

    #1

    ChIP-Seq: knockout as control?

    I have four samples.

    1) A standard ChIP for a transcription factor (TF) of interest.
    2) A standard Input DNA control (i.e. sheared, but no IP).

    3,4) Same as 1&2 but from Knockout cells completely lacking the TF.


    What's the best way to utilize these controls?

    I have been running peak callers using the Input DNA as control (i.e. 1 vs 2, and 3 vs 4). Then I subtract the overlapping peaks found in the knockout peak calling data from those in the wild-type.

    Would it be better to run the peak analysis using just 1 vs 3 (i.e. wild-type ChIP vs knockout ChIP)? What's the ideal way to do this?

    Thanks for any ideas
  • kopi-o
    Senior Member
    • Feb 2008
    • 319

    #2
    There is probably no "right answer" but your approach seems good to me. It seems more rigorous than ChIP-seq analyses usually are.

    Comment

    • HESmith
      Senior Member
      • Oct 2009
      • 512

      #3
      If the input samples 2 and 4 are identical, then you can directly compare experimental samples 1 and 3. If not, then the approach you're using is better than direct comparison.

      Comment

      • Combo
        Junior Member
        • Sep 2009
        • 8

        #4
        Thanks for the responses.

        At this stage I'm trying to make the best of the data. It definitely has problems -- e.g. even after lots of MACS parameter optimization, a 'known' enrichment area only shows up in the peaks results with an FDR ~20%. I don't think I've seen any papers using such a high cut off.

        Any thoughts on this or what changes could be made to improve it? I've tried many combinations of 'keepdup' and 'mfold', which have helped, but I'm running out of ideas now as far as making this validated enrichment area show up with a low FDR.

        I will try the 1 vs 3 comparison later today. Maybe that will help.
        Last edited by Combo; 11-03-2011, 12:13 PM.

        Comment

        • Combo
          Junior Member
          • Sep 2009
          • 8

          #5
          Interestingly enough, performing MACS peak calling with the knockout pulldown as control (1 vs 3) improved the FDR of the peak within the validated/known occupancy region considerably.

          Perhaps I will next run MACS on the knockout vs knockout input, then subtract those peaks from the above.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Today, 02:55 AM
          0 responses
          5 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          11 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-23-2026, 11:41 AM
          0 responses
          11 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          24 views
          0 reactions
          Last Post SEQadmin2  
          Working...